Bacterial extracellular vesicles as emerging platforms to combat multidrug-resistant bacterial infections: Mechanisms, therapeutic applications, and future prospects Authors: Zhijian Zhou, Yaoqiang Shi, Yu Fu, Yafei Huang, Yuzhu Song, Chao Li Published: 2026 ABSTRACT ABSTRACTMultidrug-resistant bacteria (MDRB) have become a global health crisis that challenges the effectiveness of conventional antibiotics. Bacterial extracellular vesicles (BEVs) are nanoscale bilayered membrane vesicles secreted by both Gram-positive and Gram-negative bacteria. They can encapsulate proteins, lipids, and nucleic acids, and transfer these molecules between bacteria and host cells without direct contact. Owing to their natural ability to transport bioactive molecules, BEVs have recently gained attention as potential anti-infective platforms. They can deliver antimicrobial agents directly to resistant pathogens and act as vaccine carriers by triggering innate and adaptive immunity. Advances in BEV isolation, drug loading, and bioengineering have expanded their therapeutic potential. However, challenges such as large-scale manufacturing, immunogenicity control, and regulatory standardization still hinder clinical translation. This review summarizes the mechanisms, engineering strategies, and biomedical applications of BEVs against MDRB and discusses future perspectives for their safe and effective clinical use as antimicrobial nanoplatforms.KEYWORDS: Bacterial extracellular vesicles, multidrug-resistant bacteria, drug delivery systems, vaccine development, antimicrobial nanotechnology Introduction Multidrug-resistant bacteria (MDRB) have rapidly spread worldwide in recent years, becoming a major threat to public health [1,2]. Between 1990 and 2021, more than one million people died each year from MDRB infections, and the number is projected to reach 1.91 million by 2050 [3]. This rising burden is closely linked to the misuse and overuse of antibiotics, which accelerate the emergence and spread of resistant strains. Under continuous selective pressure, MDRB developed multiple defense mechanisms, including target modification, enzymatic inactivation, and efflux pump activation [4], all of which greatly weaken the efficacy of current antibiotics (Figure 1). Recognizing the severity of this crisis, the World Health Organization has listed carbapenem-resistant Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa as critical-priority pathogens that demand new therapeutic solutions (Table 1) [5]. As these pathogens continue to expand and treatment options decline, the development of sustainable and effective alternative strategies has become increasingly urgent. Overview of bacterial antibiotic resistance: mechanisms, gene spread, and clinical consequences. (a) Bacterial drug resistance mechanisms include target modification, drug efflux pumps, and enzymatic inactivation such as β-lactamase production, leading to reduced antibiotic efficacy. (b) Resistant genes are propagated through plasmid exchange and selective pressure, resulting in the enrichment of resistant bacterial populations. (c) The consequences of antibiotic resistance include treatment difficulties, increased healthcare costs, higher mortality, and severe public health crises. Together, these processes highlight the urgent need for alternative therapeutic strategies against MDRB. This figure was created by Figdraw. Table 1.The World Health Organization provides an updated list of priority pathogens.Priority classDrug-resistant speciesBacterial speciesCritical groupCarbapenem resistantEnterobacteralesCarbapenem resistantAcinetobacter baumanniiThird-generation cephalosporin-resistantEnterobacteralesRifampicin-resistantMycobacterium tuberculosisHigh groupVancomycin-resistantEnterococcus faeciumMethicillin-resistantStaphylococcus aureusFluoroquinolone-resistantSalmonella TyphiFluoroquinolone-resistantShigella spp.Fluoroquinolone-resistantNon-typhoidal SalmonellaCarbapenem-resistantPseudomonas aeruginosaThird-generation cephalosporin-and/or fluoroquinolone-resistantNeisseria gonorrhoeaeMedium groupAmpicillin-resistantHaemophilus influenzaeMacrolide-resistantStreptococcus pneumoniaeMacrolide-resistantGroup A streptococciPenicillin-resistantGroup B streptococci The World Health Organization provides an updated list of priority pathogens. Among emerging biological approaches, bacterial extracellular vesicles (BEVs) have gained increasing attention [6]. BEVs are nanoscale membrane vesicles secreted by Gram-positive and Gram-negative bacteria. They contain diverse biomolecules, including proteins [7,8], lipids [9], RNA [10–12], and DNA [13], which contribute to bacterial communication, virulence, and immune modulation [14,15]. Through these molecules, BEVs mediate cell signaling, gene transfer, and the transport of virulence factors, enabling bacterial adaptation in complex environments [16]. Their ability to interact with host cells provides new insight into host-pathogen communication and has inspired growing biomedical interest [17]. By delivering bacterial components and influencing immune pathways [18], BEVs provide important biological functions that can be harnessed for antimicrobial therapy. As AMR rises and antibiotics lose effectiveness [19], these vesicles are receiving increasing attention as alternative or complementary therapeutic systems [20]. They can present bacterial antigens [21–24] and immune-active molecules [25–28] that elicit protective responses without replication [29,30]. For example, modified BEVs enhanced protection against Helicobacter pylori infection [31]. Compared with live or attenuated vaccines, BEVs are safer, more controllable [29,32], and less likely to cause systemic immune reactions [33]. In addition to their immunogenic features, BEVs show great potential as natural drug delivery carriers [34,35]. Their nanoscale size and modifiable surface allow efficient encapsulation of therapeutic molecules and targeted delivery to infection sites [36]. Wei et al. designed engineered BEVs capable of targeting Acinetobacter baumannii, achieving effective antibacterial action [37]. These studies suggest that BEVs can function as drug carriers, immune modulators, and vaccine adjuvants in combating MDRB infections [38]. Although progress has been made, several limitations remain. Current detoxification strategies have reduced the toxicity of BEVs [32], but systematic evaluation of their immunogenicity and biosafety is still lacking [39]. The pharmacokinetics and biodistribution of BEVs also require further investigation, as their tissue distribution and clearance vary with administration routes. These uncertainties make it difficult to establish optimal dosing and safety profiles for clinical application. Moreover, large-scale manufacturing, quality control, and regulatory standardization remain critical challenges. While GMMA-based Shigella vaccines have reached phase II clinical trials [40], broader applications of BEVs in treating MDRB infections still demand further research and clinical validation. In summary, BEVs play a key role in bacterial communication and host interaction and have great potential for antimicrobial therapy. This review discusses the current challenges of MDRB treatment and outlines recent advances in BEV isolation, drug loading, and therapeutic applications. It also highlights emerging opportunities for using BEVs in immune modulation and vaccine development, as well as the future directions needed to achieve clinical translation. BEVs isolation techniques BEV isolation methods have progressed from early ultracentrifugation protocols to a diverse range of modern techniques aimed at improving yield, purity, and structural integrity, as summarized in Table 2. The choice of isolation strategy strongly influences the particle size distribution, biological activity, and downstream applicability of BEVs [41]. In addition, external stressors, such as antibiotic exposure, can alter vesicle secretion and cargo composition, further highlighting the importance of standardized and carefully optimized isolation procedures [6]. Table 2.Isolation technique of bacterial extracellular vesicles.PeriodTechniqueAdvantagesDisadvantagesInitialDifferential centrifugationHigh purity, wide application range, low costThe device is time-consuming,requires high requirements,may cause damageCurrentDensity gradient centrifugationThe separation effect is good, the pure particles can be obtained at one time, the adaptation range is wide, the particles will not be squeezed and deformed, and the particle activity can be maintainedCentrifugation time is long, need to prepare the inert gradient medium solution, the operation is strict, not easy to masterUltrafiltrationSimple operation, mild conditions, suitable for the separation of heat-sensitive substances, no phase change, no need to add chemical reagents, no pollutionNot possible to directly obtain dry powder preparations, and generally only a concentration of 10 to 50% can be obtained for protein solutionsImmunosorbent methodThe target BEVs can be specifically isolated and purified with high purity and relatively simple operationSpecific antibodies are required, nonspecific binding may be present, and the cost is higherMethod of precipitationSimple operation, low cost, no need for expensive equipment, suitable for large-scale preparationThe purity is relatively low, contamination by precipitating agents may be introduced, and the physical properties of the precipitate are uncertainMolecular volume exclusion chromatographyHigh separation efficiency, not affected by shear force, fast elutionNeed special equipment Isolation technique of bacterial extracellular vesicles. Differential centrifugation remains the most used method due to its simplicity and accessibility. By applying sequential centrifugation steps at increasing speeds, particles of different sizes are gradually removed, enabling basic enrichment of BEVs [42–44]. Density gradient centrifugation further improves purity by separating vesicles according to their buoyant density, often between 1.10 and 1.19 g/mL. This approach reduces physical damage and preserves vesicle activity, although it is time-consuming and requires strict operational control [45–47]. Ultrafiltration is another widely used method that relies on membrane filters with defined molecular weight cutoffs. It allows rapid concentration of BEVs under mild conditions and avoids chemical contamination. However, it may not provide high purity and often requires additional purification steps [45–47]. Immunoaffinity capture offers greater specificity by using antibodies against BEV surface markers such as OmpA or Omp34. This approach achieves high purity but is costly and difficult to scale up [48,49]. Precipitation-based methods, including polyethylene glycol and trichloroacetic acid precipitation, provide a simple and low-cost means for large-scale isolation. Their major limitation is the co-precipitation of contaminants, which may require secondary purification [50,51]. Size-exclusion chromatography (SEC), using media such as Sepharose CL-2B or qEV columns [52], has gained popularity for its gentle separation process and minimal impact on vesicle integrity. It offers high reproducibility and is suitable for downstream functional studies [51,53]. More recent advances have introduced microfluidic systems, magnetic bead-based platforms, aptamer-guided capture methods, and improved chromatographic technologies [53–61]. Microfluidic chips allow rapid, continuous processing with low sample consumption [54]. Magnetic bead-based and aptamer-assisted methods provide high selectivity by binding specific vesicle surface antigens [57,58]. Meanwhile, next-generation SEC and hybrid chromatographic systems further enhance throughput and purity, making them promising for clinical-grade BEV preparation [53,59]. Each isolation technique has distinct strengths and limitations in purity, scalability, processing time, and preservation of vesicle structure. Therefore, method selection should be guided by experimental goals, sample properties, and downstream applications. Optimizing isolation conditions is essential for ensuring the structural integrity and functional activity of BEVs, which ultimately determines their reliability as therapeutic and research tools. Drug loading strategies for BEVs Effective drug loading is essential for maximizing the therapeutic potential of BEVs. Because BEVs possess a natural lipid bilayer and an internal aqueous core, they can encapsulate both hydrophilic and hydrophobic agents [62]. However, loading efficiency varies widely across different techniques, and the choice of method influences vesicle integrity, drug retention, and downstream biological performance [63]. The major strategies are summarized in Table 3 and include electroporation, ultrasonication, freeze – thaw cycling, simple incubation, dialysis, lipid fusion and extrusion (Figure 2). Selecting a suitable method requires balancing drug physicochemical properties, vesicle stability and expected application scenarios. Table 3.Technique of antimicrobial drug loading in bacterial extracellular vesicles.TechniquePrincipleAdvantagesDisadvantagesElectroproationUsing an electric field to create temporarypores in bacterial cell membranes to increase cell membrane permeabilityProvides a noninvasive, physical method to enhance vesicle permeability for drug loading without the use ofharsh chemicalsCan potentially damage vesicleintegrity and cause cell lysis if not carefully controlledUltrasonicationThe application of ultrasonic waves to enhancethe permeability of the vesicle membranes,allowing for the encapsulation of drugsUltrasound can enhance drug loading efficiencyby improving vesicle membrane permeability through cavitation effectsHigh energy input may lead to vesiclerupture or aggregation. affecting vesiclequality and yieldFreeze-thaw cyclesUsing freeze-thaw cycles involves useuseofalternating freezing and thawing todisrupt the vesicle membrane, facilitatingthe vincorporation of drugs into the vesiclesCycles of freezing and thawing can disruptvesicle membranes, allowing for drugincorporationRepeated freeze-thaw cycles might lead tovesicle degradation or loss of biologicalactivitySimple incubationThe direct exposure of vesicles to drugsunder controlled conditions to facilitatedrug incorporation into the vesiclestructureA straightforward approach that allows forspontaneous drug uptake by vesicles undercontrolled conditionsMay result in low drug loading efficiencyand potential for nonspecific drugencapsulationDialysisThe use of a semipermeable membrane toseparate and concentrate the drug withinthe vesicles, enhancing the encapsulation efficiencyEnables the selective loading of drugsbased on size exclusion, without theneed for high energy inputRequires specialized equipment and mayhave a slow drug loading rateLipid fusionThe use of lipid bilayers to merge with BEVmembranes, facilitating the incorporationof hydrophobic drugs into the vesicle structureCan facilitate the loading of hydrophobicdrugs by merging lipid bilayers withvesicle membranesThe fusion process can be complex to controland may lead to vesicle aggregation or fusionwith unintended structuresExtrusionForcing the vesicles through a narrow aperture,which increases membrane fluidity and allowsfor the incorporation of drugs into the BEVsA mechanical method that can be used toforce drugs into vesicles through a narrow apertureHigh pressure can damage vesicle structure, andthe process may be difficult to scale up Technique of antimicrobial drug loading in bacterial extracellular vesicles. Representative methods for drug loading into BEVs. Seven strategies are illustrated: (a) electroporation, (b) ultrasonication, (c) freeze-thaw cycles, (d) simple incubation, (e) dialysis, (f) lipid fusion, and (g) extrusion. Each approach promotes drug entry through physical or chemical membrane disruption followed by ultracentrifugation for purification. These techniques differ in loading efficiency, scalability, and preservation of vesicle integrity, highlighting the need for method optimization based on drug properties and application requirements. This figure was created by Figdraw. Electroporation creates temporary pores in the BEV membrane through a controlled electric field [64,65]. These pores allow drugs to enter the vesicle interior. Electroporation enables rapid loading and does not require chemical additives. It is particularly useful for hydrophilic cargos and genetic materials. However, high voltage can damage vesicle membranes, reduce structural integrity, and cause variable loading efficiency. Optimization of pulse strength and duration is therefore essential for maintaining BEV viability. Ultrasonication uses ultrasonic waves to promote drug entry by temporarily increasing membrane permeability [66,67]. Cavitation events generated during the process enhance loading efficiency and support the encapsulation of different drug types. This method can allow high-throughput processing. Nevertheless, prolonged or intense sonication may rupture vesicles or cause aggregation, which compromises vesicle quality. Careful control of intensity and duration is required to preserve bioactivity. Freeze – thaw cycling facilitates drug incorporation by repeatedly freezing and thawing the vesicle suspension [68]. Temperature-driven membrane disruption creates transient gaps that enable drug entry. The method is simple and requires no specialized equipment. However, excessive cycles can lead to membrane damage, reduced vesicle stability, and loss of biological activity. It is best suited for applications requiring moderate loading without strict structural constraints. Simple incubation relies on spontaneous diffusion of drugs across the vesicle membrane under controlled temperatures and concentrations [69–71]. This method is mild, preserves vesicle structure and is easy to implement. However, loading efficiency is often low, and nonspecific drug adsorption may occur. Incubation is more appropriate for small molecules with favorable membrane permeability. Dialysis uses a semipermeable membrane to concentrate drugs inside vesicles based on size exclusion [72–74]. It avoids harsh physical forces and supports stable loading while preserving vesicle morphology. The technique is advantageous for delicate or heat-sensitive molecules. Its limitations include long processing times and reliance on specialized equipment, making scale-up challenging. Lipid fusion introduces exogenous lipid bilayers that merge with the BEV membrane [75,76]. This technique allows hydrophobic drugs to embed into lipid layers and supports vesicle engineering through membrane remodeling. Controlling fusion efficiency can be difficult, and inappropriate conditions may cause vesicle aggregation or nonspecific fusion with unwanted structures. Despite these challenges, lipid fusion provides unique opportunities for constructing hybrid vesicles with enhanced functionality. Extrusion forces BEVs through membranes with defined pore sizes to increase membrane fluidity and allow drug insertion [77,78]. This mechanical method is effective for homogenizing vesicle size and improving loading consistency. High pressure may damage vesicle morphology, and the process can be difficult to scale. However, when optimized, extrusion provides a reliable strategy for producing uniformly loaded BEVs suitable for downstream delivery studies. Each loading method has advantages and limitations related to efficiency, scalability, vesicle integrity, and compatibility with specific therapeutic agents. Therefore, the selection of a loading strategy should be guided by drug chemistry, the desired release profile, and the structural stability required for therapeutic applications. Continued refinement of loading conditions and the development of hybrid loading approaches will help improve the performance of BEV-based drug delivery systems and support their clinical translation. Engineering and functionalization strategies of BEVs Engineering and functionalization of BEVs are essential for translating these naturally secreted nanostructures into controllable and application-oriented therapeutic platforms. Rather than exhibiting fixed biological properties, BEVs can be rationally engineered to improve biosafety, production efficiency, and surface functionality, thereby enhancing their suitability for downstream biomedical applications. A primary level of BEVs engineering involves genetic modification of parental bacterial strains, which directly regulates vesicle biogenesis and membrane composition. Deletion of the lipid A acyltransferase gene msbB has been widely employed to attenuate LPS endotoxicity by altering lipid A structure, leading to reduced inflammatory potential of BEVs while preserving immunogenicity [79]. In addition, disruption of genes involved in outer membrane integrity, such as components of the Tol-Pal system [80,81], consistently enhances vesicle release in Gram-negative bacteria. Similar effects have been observed following deletion or modification of outer membrane proteins, including OmpA and Lpp [18,71], which weaken membrane-peptidoglycan interactions and promote vesiculation. Collectively, these strain-level engineering strategies primarily address two major translational challenges of BEVs: excessive endotoxin-associated toxicity and insufficient vesicle yield. Beyond genetic regulation of vesicle production, post-assembly functionalization strategies enable BEVs to acquire programmable surface properties. Surface protein display represents one of the most extensively explored approaches, allowing heterologous proteins, peptides, or ligands to be anchored on the vesicle membrane. ClyA [82] is frequently used as a fusion scaffold due to its efficient outer membrane localization and stable incorporation into BEVs [80]. In addition, autotransporter systems [83,84] and other self-translocation mechanisms facilitate oriented protein presentation on vesicle surfaces [81–83]. Modular coupling systems, such as SpyTag/SpyCatcher, further enable site-specific and covalent protein attachment with controlled density and orientation [84]. Alternative anchoring strategies, including ice-nucleating proteins [85] and the CotC system derived from Bacillus subtilis [85], expand the applicability of surface display across different bacterial species. Chemical functionalization provides an additional layer of control over BEV surface properties. Bioorthogonal conjugation techniques, particularly click chemistry-based approaches, allow precise attachment of functional molecules to BEV membranes under mild conditions without altering the parental strain [79]. Together, these genetic and chemical engineering strategies form a modular toolkit for tailoring BEVs with improved biosafety, targeting capability, and functional versatility, providing a logical foundation for the therapeutic and vaccine applications discussed in subsequent sections. Applications of BEVs in combating MDRB infections Natural antibacterial activity of BEVs Many bacterial species secrete BEVs with intrinsic antibacterial capabilities [86]. These vesicles contain enzymes, secondary metabolites, lipids, and other functional molecules that help bacteria compete within complex microbial communities [87]. Such intrinsic properties provide the biological foundation for using BEVs as anti-MDRB agents. Morici et al. found that BEVs derived from Burkholderia thailandensis exhibit broad-spectrum antimicrobial activity. Their vesicles contain peptidoglycan hydrolases, long-chain rhamnolipids, and 4-hydroxy-3-methyl-2-(2-nonenyl) quinoline, which collectively suppress MRSA growth and disrupt biofilm formation [88]. These multifunctional components highlight the ability of BEVs to target essential bacterial structures and communication systems. Similarly, Evans et al. reported that Myxococcus xanthus, a well-known predatory bacterium, produces BEVs enriched with proteases, phosphatases, and specialized secondary metabolites. These BEVs were able to kill E. coli efficiently, demonstrating an innate predatory mechanism distinct from traditional antibiotics [89]. This biological activity is particularly valuable because vesicle-associated enzymes can degrade cell walls, membranes, and biofilm matrices, making BEVs powerful natural competitors in polymicrobial environments. These studies collectively suggest that BEVs themselves possess antimicrobial properties independent of external loading. This intrinsic activity provides a conceptual basis for using BEVs as natural antibacterial agents against MDRB. Engineered BEVs for targeted antimicrobial therapy Although natural BEVs exhibit antibacterial properties, engineering strategies significantly expand their therapeutic potential. Through genetic manipulation, membrane modification, or integration with functional materials, BEVs can be designed to carry antibiotics, nucleic acids, immunomodulators, or combined therapeutic systems (Figure 3). Schematic overview of BEVs as antibacterial delivery vehicles. BEVs originate from naturally occurring or engineered bacteria and are released as 20–400 nm vesicles through membrane projection and vesicle separation (a) different therapeutic cargos, including antibiotics, antimicrobial peptides and gene-editing systems, can be packaged into BEVs to form “drug parcels” (b) drug-loaded BEVs recognize incoming bacteria or biofilms via receptor-mediated specific binding and quorum-sensing signals, enabling precise targeting of pathogens such as MRSA and carbapenem-resistant enterobacteriaceae (cre) (C) at the infection site, environmental pH changes and enzymatic degradation trigger the release of antibacterial substances, resulting in bacterial growth inhibition or cell death (d) at the infection site, pH variation and enzymolysis destabilize BEVs and trigger the release of antibacterial substances, leading to bacterial growth inhibition or cell death. This figure was created by Figdraw. Antibiotic and antimicrobial substance delivery Using BEVs as antibiotic delivery vehicles has been widely explored due to their structural compatibility, stability, and efficient uptake by host cells and bacteria. Ma et al. designed BEV-based nanoantibiotics that encapsulate ceftriaxone and amikacin. The BEVs protected these drugs from premature degradation, enhanced their accumulation at infection sites, and significantly improved bactericidal efficacy compared with free antibiotics [90]. This strategy reduces the required dose and maximizes drug-on-target effect while minimizing systemic toxicity. Tashiro et al. used BEVs to transport levofloxacin (LEV) for the treatment of enterotoxigenic E. coli [91]. Their study demonstrated that orally administered LEV-BEVs accumulated efficiently in the small intestine, remained for extended periods, and reduced bacterial burden much more effectively than LEV alone [91]. Such delivery systems not only improve drug localization but also prolong therapeutic duration. Moreover, BEVs can encapsulate other antibiotics including gentamicin, which was effectively delivered to Buttiauxella agrestis using BEV carriers [91]. These findings show that BEVs improve antibiotic solubility, membrane permeability, and biofilm penetration, making them promising platforms for overcoming resistance barriers. In addition to traditional antibiotics, BEVs can carry antimicrobial peptides, quorum-sensing inhibitors, and metabolic disruptors, creating an expanded landscape of anti-MDRB applications [92]. Genetic material delivery BEVs can deliver genetic materials such as siRNA, plasmids, gene-editing tools, and antisense constructs to MDRB [93]. This therapeutic direction seeks to eliminate bacteria not through chemical killing but by directly disabling resistance genes or essential survival pathways. Jin et al. engineered cationic lipid-hybrid BEVs to deliver CRISPR/Cas9 plasmids targeting MDR P. aeruginosa and A. baumannii. Once internalized, the CRISPR/Cas9 system induced lethal DNA cleavage, causing rapid bacterial death [94]. This approach operates with high precision, bypassing conventional resistance mechanisms. Gene delivery via BEVs provides advantages including natural membrane compatibility, reduced immune clearance, and efficient bacterial uptake. Thus, BEVs may serve as next-generation precision tools for combating MDRB through genomic disruption rather than conventional antibiotics. Synergistic and multimodal therapy Beyond single-agent delivery, combining BEVs with nanomaterials or physical stimuli yields synergistic therapeutic effects. These hybrid systems enhance drug delivery, prolong retention time, improve targeting, and introduce additional antibacterial mechanisms. Yang et al. developed a BEV-MXene composite system that showed enhanced photothermal performance under near-infrared irradiation. BEVs increased MXene stability, and elevated temperatures promoted vesicle permeability and drug release. This multimodal system achieved nearly complete eradication of MDRB in vitro and in vivo [95]. Wei et al. designed engineered BEVs displaying a ClyA-scFv antibody fragment that recognizes P. aeruginosa PcrV protein. When combined with a liposomal drug system, the platform showed precise targeting and amplified antimicrobial effects in infection models [37,96]. This demonstrates how surface-engineered BEVs can be integrated with existing drug systems for combinational therapy. Guo et al. constructed a biomineralized BEV system loaded with lysozyme, mupirocin, and pH-responsive CaCO3 cores. The vesicles accumulated at infection sites and released antimicrobial agents in response to acidic environments, effectively clearing S. aureus in vivo [97]. Further studies show BEVs can co-deliver β-lactams and β-lactamase inhibitors simultaneously, restoring antibiotic sensitivity in resistant bacteria [98,99]. Ultrasound-responsive BEV-coated platforms [100] and BEV-based hydrogel systems capable of responding to urinary tract infection microenvironments [101] illustrate how BEVs can be incorporated into advanced biomaterials for site-specific therapy. Collectively, these multimodal systems demonstrate that BEVs can function not only as carriers but also as bioactive components within engineered nanotherapeutic platforms. Vaccine development based on BEVs Natural BEV-Based vaccines BEVs contain lipopolysaccharides, outer membrane proteins, lipids, and pathogen-associated molecular patterns that naturally stimulate immune responses [102]. These intrinsic components enable BEVs to function as self-adjuvanting vaccine platforms capable of inducing both innate and adaptive immunity. Hegstad et al. demonstrated that BEVs derived from Enterococcus faecium effectively activated immune responses in rabbits. Serum from immunized animals showed bactericidal activity against multiple Enterococcus strains, including vancomycin-resistant isolates. Their results indicated that BEVs enhanced neutrophil-mediated phagocytosis and stimulated both innate and adaptive immunity [103]. Morici et al. developed a BEV-based adjuvant derived from Bordetella pertussis. When co-administered with pertussis antigens such as pertussis toxin and filamentous hemagglutinin, the BEV formulation induced strong IgG1 and IgG2a responses and activated Th1/Th17 cytokine pathways [104]. This vaccine also enhanced memory immune responses and slowed the decline of post-immunization immunity, addressing a major limitation of acellular pertussis vaccines. Natural BEVs also provide advantages in antigen presentation by preserving the native conformation of surface proteins. This helps maintain conformational epitopes that are often lost during recombinant protein purification. As a result, BEV-based vaccines may generate broader antibody repertoires and stronger neutralizing responses. In addition, because their components are derived directly from bacterial membranes, BEVs often contain multiple immunostimulatory motifs in physiologically balanced proportions. This natural adjuvanticity reduces the need for external adjuvants and lowers formulation complexity. These properties collectively highlight the potential of unmodified BEVs as safe, stable, and cost-effective vaccine candidates, especially for pathogens with limited vaccine options. Engineered BEV-Based vaccines Genetic and surface engineering strategies can enhance antigen presentation, improve targeting, and reduce potential side effects. BEVs can display recombinant antigens [105], fused peptides, or immunostimulatory factors [106], enabling precise design of vaccines against specific pathogens. One key mechanism involves the engagement of TLR2-mediated IL-10/Treg pathways rather than strong TLR4-LPS activation. This pattern favors protective immunity without triggering excessive inflammation [107,108](Figure 4). Such controlled immunomodulation is advantageous for developing safe vaccines. Luirink et al. demonstrated that Salmonella BEVs engineered to display pneumococcal antigens elicited strong IL-17A responses and protective antibodies. The engineered BEVs significantly reduced Streptococcus pneumoniae colonization, offering a promising mucosal vaccination strategy [109]. Liu et al. expressed Helicobacter pylori antigens (UreB, VacA, CagA) on the surface of BEVs, which induced potent humoral and mucosal immune responses, characterized by mixed Th1/Th2/Th17 activation [31,110]. Immunized mice showed strong protection against gastric infection, demonstrating the effectiveness of BEVs in mucosal vaccine design. Importantly, the multivalent presentation on the vesicle surface can mimic native pathogenic structures, enhancing immune recognition. Furthermore, engineering BEVs for controlled LPS modification can optimize safety without sacrificing immunogenic potency. The ability to fine-tune antigen density, orientation, and membrane composition provides a versatile platform for rational vaccine design tailored to MDRB with complex immune evasion mechanisms. Immune activation and antibacterial effects induced by BEVs. BEVs stimulate innate and adaptive immunity through PAMP recognition and antigen presentation. PAMPs activate TLR4/TLR5-MyD88 signaling, leading to NF-κB pathway activation and secretion of IL-6, IL-12, and TNF-α. Dendritic cells and macrophages present antigens via MHC I and II to activate CD4+ and CD8+ T cells. CD4+ T cells differentiate into Th1/Th17 subsets that secrete proinflammatory cytokines and activate B cells. B cells further differentiate into plasma cells producing IgG and IgA antibodies, which neutralize toxins, enhance phagocytosis, and inhibit bacterial adhesion and biofilm formation. Memory B/T cells enable rapid responses and efficient killing of MDRB. This figure was created by Figdraw. Hybrid and biomimetic BEV-Based vaccines Hybrid BEV vaccines combine natural vesicle components with nanoparticles, immune cell membranes, or synthetic materials to enhance antigen presentation, targeting, and stability. Zhang et al. developed A. baumannii BEV-coated nanoparticles that provided protection against both pneumonia and sepsis caused by MDRB [111]. Liu et al. created hybrid membrane vesicles by fusing BEVs from K. pneumoniae with alveolar macrophage membranes. This design enabled rapid activation of mucosal and cellular immunity and protected mice from lethal pneumonia [112]. Ding et al. constructed a multi-antigenic nano-vaccine by combining gold nanoparticles with hybrid vesicles containing both bacterial and macrophage membrane components. The nano-vaccine simultaneously targeted bacterial cells and toxins and achieved near-complete elimination of P. aeruginosa in sepsis and pneumonia models [113]. Han et al. developed the LPS@DMON@OMV nanovaccine, which activated dendritic cells in draining lymph nodes and produced antibody titers far higher than those induced by free BEVs [114]. Hybrid BEV systems offer additional opportunities for tuning immune responses. Incorporating inorganic cores can prolong antigen release, enhance lymph-node trafficking, and improve vesicle stability under physiological stress. Meanwhile, coating BEVs with immune cell membranes supports enhanced antigen capture and cross-presentation. These attributes are particularly valuable for MDRB that require strong cellular immunity for effective clearance. Hybrid systems also allow combination of antimicrobial, immunomodulatory, and adjuvant functions within a single platform, enabling multi-layered protection that mimics natural host defense mechanisms. Such versatility positions hybrid BEVs as a promising direction for next-generation antibacterial vaccines. Discussion BEVs demonstrate strong potential as innovative tools for combating MDRB [38,115] (Table 4). Their unique biomolecular composition, natural biocompatibility, and intrinsic ability to deliver proteins, nucleic acids, and antimicrobial substances position them as promising next-generation antimicrobial platforms. Engineered BEVs further extend these advantages by improving targeting, enhancing loading efficiency, and integrating multiple therapeutic modalities. Collectively, current evidence suggests that BEVs can address several limitations associated with conventional antibiotics, including poor penetration into biofilms, rapid drug degradation, and limited intracellular delivery. Despite these advances, several scientific and technical challenges continue to hinder the clinical translation of BEV-based therapies. One key issue is large-scale production. Current isolation methods, such as ultracentrifugation or density-gradient purification, can yield high-quality vesicles but remain labor-intensive and difficult to scale [116,117]. Maintaining vesicle purity, size uniformity, and structural integrity during large-batch production remains a significant barrier. Batch-to-batch variability also complicates quality control and weakens reproducibility, particularly when therapeutic BEVs require precise cargo loading or surface engineering [118]. Immunogenicity represents another major challenge. Although detoxification strategies such as GMMA and msbB deletion can attenuate endotoxin activity [83], BEVs can still activate inflammatory pathways under certain conditions. Their interactions with innate immune receptors vary depending on vesicle composition, strain background, and engineering method. A detailed understanding of how BEVs influence cytokine responses, complement activation, and long-term immune memory is essential to ensure safety. In addition, biodistribution and pharmacokinetics are still poorly defined [119,120]. Existing studies indicate that administration route strongly affects tissue distribution and clearance, which complicates dosage design, safety evaluation, and treatment optimization [121,122]. Further challenges arise from the need for more efficient and controlled engineering strategies. While genetic and chemical modifications can improve targeting or reduce toxicity, certain methods may also disrupt membrane integrity or alter vesicle stability. Achieving precise and stable surface modification without compromising vesicle function remains a critical goal. Similarly, drug-loading techniques require optimization to balance loading efficiency, cargo retention, and vesicle viability. A more systematic comparison of electroporation, ultrasonication, lipid fusion, and hybrid loading methods is needed to establish best practices for specific therapeutic applications. Table 4.Summary of key therapeutic applications of BEVs against MDRB infections.Therapeutic applicationKey technologies/strategiesAdvantages of BEVsRepresentative research focus/trendIntrinsic antibacterial activityNatural antimicrobial components carried by BEVsBroad-spectrum antibacterial effects without external modificationExploration of BEVs as natural antibacterial agents to inhibit MDRB growthDrug delivery & antimicrobial therapyAntibiotic and antimicrobial substance loading and deliveryEnhanced drug stability, targeted delivery, improved penetration, reduced side effectsDevelopment of BEV-based nanoantibiotics and targeted antimicrobial delivery systemsGenetic delivery & combinatorial strategiesGene delivery, CRISPR systems, multimodal and synergistic therapiesHigh delivery efficiency, precision targeting, overcoming resistance mechanismsBEVs for gene-based antibacterial therapy and synergistic multimodal treatmentNatural BEV-based vaccinesUse of native BEVs as immunogenic carriersSelf-adjuvant properties, induction of innate and adaptive immunityDevelopment of natural BEV vaccines against MDRBEngineered BEV-Based vaccinesGenetic engineering and surface antigen displayTunable immunogenicity, enhanced vaccine efficacy and safetyEngineered BEVs for antigen-specific immune responsesHybrid and biomimetic BEV-Based vaccinesHybrid vesicles and biomimetic nanoplatformsImproved immunogenicity, stability, and multifunctionalityIntegration of BEVs with nanotechnology to enhance vaccine performance Summary of key therapeutic applications of BEVs against MDRB infections. From a translational perspective, regulatory pathways for BEV-based therapies remain underdeveloped. The absence of standardized manufacturing protocols, potency assays, and safety evaluation frameworks poses challenges for clinical approval. To advance BEVs toward clinical use, it will be necessary to develop validated analytical tools to characterize vesicle composition, purity, and biological activity. Harmonized guidelines for defining identity, potency, sterility, and stability will also be essential. Furthermore, rigorous long-term studies are required to evaluate biodistribution, immunotoxicity, and potential off-target effects. Progress in BEV-based therapeutics will rely on continued multidisciplinary innovation. Advances in synthetic biology may enable precise control of vesicle biosynthesis and cargo loading. Nanotechnology can enhance vesicle stability, targeting, and responsiveness to microenvironmental signals. Improved bioprocessing systems, such as tangential flow filtration and microfluidic purification, may overcome production limitations and allow standardized manufacturing. Integrating BEVs with antimicrobial agents, gene-editing systems, photothermal materials, or immunomodulators could yield synergistic therapies that reduce resistance development and improve treatment outcomes. Continued progress in understanding host – pathogen interactions and immune signaling will also contribute to safer and more predictable therapeutic designs. In summary, BEVs represent a versatile and transformative platform with the potential to redefine antimicrobial therapy. Addressing the current scientific, technical, and regulatory challenges will be essential for their successful translation into clinical practice. With coordinated advances in biology, engineering, and manufacturing, BEV-based therapeutics may evolve from promising experimental tools into practical solutions for tackling the growing threat of MDRB. Funding Statement This research was funded by the Yunnan Fundamental Research Projects (202501CF070177, 202403AP140003, YNWR-QNBJ-2019–142), Major Science and Technology Projects in Yunnan Province (202202AG050013). Disclosure statement No potential conflict of interest was reported by the author(s). Data availability statement Data sharing not applicable-no new data generated: Data sharing is not applicable to this article as no new data were created or analyzed in this research. References Associated Data Data Availability Statement Data sharing not applicable-no new data generated: Data sharing is not applicable to this article as no new data were created or analyzed in this research.